These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients.
    Author: Davidson M, Losonczy MF, Mohs RC, Lesser JC, Powchik P, Freed LB, Davis BM, Mykytyn VV, Davis KL.
    Journal: Neuropsychopharmacology; 1987 Dec; 1(1):17-23. PubMed ID: 3509064.
    Abstract:
    Plasma levels of the dopamine metabolite homovanillic acid (pHVA) may potentially reflect upon central dopamine activity. This study examines the effects of debrisoquin, haloperidol, and the two drugs combined on pHVA concentrations of schizophrenic patients. Debrisoquin is a drug that suppresses the peripheral formation of homovanillic acid without affecting the central formation. Acute haloperidol administration consistently increased pHVA concentrations in patients pretreated or not pretreated with debrisoquin, suggesting that this increment reflects haloperidol's central and not peripheral effects.
    [Abstract] [Full Text] [Related] [New Search]